within Pharmacolibrary.Drugs.ATC.V;

model V04CX05
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 0.9166666666666666,
    adminDuration  = 600,
    adminMass      = 0.075,
    adminCount     = 1,
    Vd             = 0.0006,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0016666666666666668,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>13C-urea is a stable isotope-labeled form of urea used primarily as a diagnostic agent in the 13C-urea breath test for the detection of Helicobacter pylori infection. It is not used as a therapeutic agent and is approved for diagnostic use in many countries.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics estimated for healthy adults undergoing the 13C-urea breath test. No specific PK publication found; the parameters are based on general urea kinetics and clinical use of the test.</p><h4>References</h4><ol><li><p>Tanigawa, T, et al., &amp; Odomi, M (1996). Simple and rapid quantitative assay of 13C-labelled urea in human serum using liquid chromatography-atmospheric pressure chemical ionization mass spectrometry. <i>Journal of chromatography. B, Biomedical applications</i> 683(2) 135–142. DOI:<a href=&quot;https://doi.org/10.1016/0378-4347(96)00115-6&quot;>10.1016/0378-4347(96)00115-6</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/8891910/&quot;>https://pubmed.ncbi.nlm.nih.gov/8891910</a></p></li><li><p>Schellekens, RC, et al., &amp; Stellaard, F (2009). Proof-of-concept study on the suitability of 13C-urea as a marker substance for assessment of in vivo behaviour of oral colon-targeted dosage forms. <i>British journal of pharmacology</i> 158(2) 532–540. DOI:<a href=&quot;https://doi.org/10.1111/j.1476-5381.2009.00302.x&quot;>10.1111/j.1476-5381.2009.00302.x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/19732063/&quot;>https://pubmed.ncbi.nlm.nih.gov/19732063</a></p></li><li><p>Hu, YM, et al., &amp; Xu, SY (2005). Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP2C19 genotype in healthy Chinese subjects. <i>Acta pharmacologica Sinica</i> 26(3) 384–388. DOI:<a href=&quot;https://doi.org/10.1111/j.1745-7254.2005.00047.x&quot;>10.1111/j.1745-7254.2005.00047.x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/15715938/&quot;>https://pubmed.ncbi.nlm.nih.gov/15715938</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end V04CX05;
